Holen Sie sich die Stockscreener-App
1.97
2.07%
0.04
Handel nachbörslich:
1.99
0.02
+1.02%
Schlusskurs vom Vortag:
$1.93
Offen:
$1.95
24-Stunden-Volumen:
2.94M
Relative Volume:
1.20
Marktkapitalisierung:
$447.94M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-179.82M
KGV:
-1.4812
EPS:
-1.33
Netto-Cashflow:
$-159.16M
1W Leistung:
-0.51%
1M Leistung:
+44.85%
6M Leistung:
+50.38%
1J Leistung:
+138.70%
1-Tages-Spanne:
$1.845
$2.00
1-Wochen-Bereich:
$1.665
$2.02
52-Wochen-Spanne:
$0.6617
$2.23
Gossamer Bio Inc Stock (GOSS) Company Profile
Firmenname
Gossamer Bio Inc
Sektor
Branche
Telefon
(858) 684-1300
Adresse
3115 MERRYFIELD ROW, SAN DIEGO, CA
Vergleichen Sie GOSS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GOSS
Gossamer Bio Inc
|
1.97 | 438.84M | 0 | -179.82M | -159.16M | -1.33 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Gossamer Bio Inc Stock (GOSS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-14 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-06-25 | Eingeleitet | Oppenheimer | Outperform |
| 2024-04-05 | Fortgesetzt | Wedbush | Outperform |
| 2023-07-27 | Herabstufung | UBS | Buy → Neutral |
| 2023-03-07 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2023-03-01 | Eingeleitet | Guggenheim | Neutral |
| 2022-12-07 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2022-12-07 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-12-07 | Herabstufung | SMBC Nikko | Outperform → Neutral |
| 2022-10-20 | Eingeleitet | Goldman | Buy |
| 2022-09-21 | Eingeleitet | JP Morgan | Neutral |
| 2022-09-19 | Eingeleitet | Wedbush | Outperform |
| 2022-04-18 | Eingeleitet | Raymond James | Outperform |
| 2022-04-06 | Eingeleitet | UBS | Buy |
| 2022-01-10 | Hochstufung | SMBC Nikko | Neutral → Outperform |
| 2021-11-09 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2021-09-21 | Fortgesetzt | Piper Sandler | Overweight |
| 2020-06-29 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-04-22 | Eingeleitet | Piper Sandler | Overweight |
| 2020-02-27 | Eingeleitet | Barclays | Overweight |
| 2019-12-03 | Fortgesetzt | BofA/Merrill | Buy |
| 2019-10-30 | Eingeleitet | Berenberg | Buy |
| 2019-03-05 | Eingeleitet | Barclays | Overweight |
| 2019-03-05 | Eingeleitet | BofA/Merrill | Buy |
| 2019-03-05 | Eingeleitet | Evercore ISI | Outperform |
| 2019-03-05 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Gossamer Bio Inc Aktie (GOSS) Neueste Nachrichten
Gossamer Bio Reports Q2 2025 Financial Results - TipRanks
Analyzing recovery setups for Gossamer Bio Inc. investorsAI-Powered Stock Trend Movement Analysis - Newser
What machine learning models say about Gossamer Bio Inc.Free Technical Entry Strategy for Beginners - Newser
Will Gossamer Bio Inc. see short term momentumStock Portfolio Risk and Return Analysis - Newser
Is Gossamer Bio Inc. stock poised for growthGrowth Watchlist for Long Term Positioning - Newser
Multi asset correlation models including Gossamer Bio Inc.Machine Learning Intraday Signal Forecast - Newser
Institutional investors in Gossamer Bio, Inc. (NASDAQ:GOSS) see US$54m decrease in market cap last week, although long-term gains have benefitted them. - Yahoo Finance
Is Gossamer Bio Inc. trending in predictive chart modelsOversold Stock Bounce Playbook Generator - Newser
What makes Gossamer Bio Inc. stock price move sharplyReal-Time Investment Signal Forecast with AI - Newser
Real time scanner hits for Gossamer Bio Inc. explainedMarket Timing Strategy with Technical Filters - Newser
H.C. Wainwright Maintains Gossamer Bio(GOSS.US) With Buy Rating, Maintains Target Price $10 - 富途牛牛
Gossamer Bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)August 7, 2025 - BioSpace
Gossamer Bio earnings beat by $0.01, revenue topped estimates - Investing.com Australia
Gossamer Bio Reports Q2 2025 Financials, Announces PROSERA Phase 3 Topline Results Expected in February 2026, and First Site Activations for Registrational Phase 3 SERANATA Study in PH-ILD Expected in Q4 2025. - AInvest
Gossamer Bio 2025 Q2 Earnings Sharp Net Loss Amid Revenue Drop - AInvest
Gossamer Bio 2025 Q2 Earnings Sharp Net Income Decline of 177.7% - AInvest
Gossamer Bio shares fall 7.41% premarket despite beating earnings expectations. - AInvest
Gossamer Bio Inc. Exceeds Q2 Expectations Despite LossNews and Statistics - IndexBox
Gossamer Bio: Q2 Earnings Snapshot - New Haven Register
Gossamer Bio Announces Second Quarter 2025 Financial Results and Provides Business Update - BioSpace
How Gossamer Bio Inc. stock performs during market volatilityBuy and Exit Strategy Based on Momentum - Newser
Gossamer Bio shares rise 1.39% after-hours despite Q2 revenue drop of 88%. - AInvest
Gossamer Bio (GOSS) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
GOSS Achieves Strong Q2 Revenue and Prepares for Commercial Expa - GuruFocus
Gossamer Bio Reports Q2 Revenue Drop of 88% - AInvest
Gossamer Bio Q2 revenue drops 88% - MarketScreener
Gossamer Bio's 390-Patient PAH Trial Nears Crucial February Readout, $213M Cash Runway - Stock Titan
Will Gossamer Bio Inc. price bounce be sustainableFree Smart Trade Plans With Risk Protection - Newser
Can Gossamer Bio Inc. rally from current levelsStrategy Builder for Growth Focused Traders - Newser
Why is Gossamer Bio Inc. stock attracting strong analyst attentionExponentially increasing returns - Jammu Links News
Custom strategy builders for tracking Gossamer Bio Inc.Market Liquidity and Price Flow Analysis - Newser
Published on: 2025-08-04 06:30:01 - beatles.ru
Is Gossamer Bio Inc. forming a reversal patternReal-Time Investment Signal Forecast with AI - Newser
How volatile is Gossamer Bio Inc. stock compared to the marketCapitalize on market momentum for maximum gains - Jammu Links News
Why Gossamer Bio Inc. is moving todayStock Market Watch with Smart Filters - Newser
Why Gossamer Bio Inc. stock attracts strong analyst attentionLong-Term Allocation Strategy Summary Breakdown - Newser
What are the latest earnings results for Gossamer Bio Inc.Capitalize on fast-moving stock trends - Jammu Links News
What is the dividend policy of Gossamer Bio Inc. stockCapitalize on high-yield stocks early - Jammu Links News
When is Gossamer Bio Inc. stock expected to show significant growthFree Expert Stock Watchlist - Jammu Links News
How strong is Gossamer Bio Inc. company’s balance sheetUnlock daily trading alerts for profits - Jammu Links News
Is it the right time to buy Gossamer Bio Inc. stockCapitalize on stocks with high profit margins - Jammu Links News
How does Gossamer Bio Inc. compare to its industry peersInvest smarter with real-time trading alerts - Jammu Links News
Does Gossamer Bio Inc. stock perform well during market downturnsAchieve breakthrough profits with smart strategies - Jammu Links News
Gossamer Bio Inc. Stock Analysis and ForecastAmplify your gains with low-risk picks - Jammu Links News
What institutional investors are buying Gossamer Bio Inc. stockBuild a portfolio that stands the test of time - Jammu Links News
How many analysts rate Gossamer Bio Inc. as a “Buy”Discover market opportunities others miss - Jammu Links News
What catalysts could drive Gossamer Bio Inc. stock higher in 2025Double-digit growth - Jammu Links News
What are analysts’ price targets for Gossamer Bio Inc. in the next 12 monthsFree Stock Selection - Jammu Links News
Regression analysis insights on Gossamer Bio Inc. performanceFree Trade Ready Stock Watch for Short Term - Newser
Is this a good reentry point in Gossamer Bio Inc.Smart Entry Signals for Active Traders - Newser
Institutional scanner results for Gossamer Bio Inc.Free Smart Trade Plans With Risk Protection - Newser
Finanzdaten der Gossamer Bio Inc-Aktie (GOSS)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.67%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):